GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led ...

We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

Cystic fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

BofA Securities, Goldman Sachs & Co. LLC, Evercore ISI, Guggenheim Securities and Cantor acted as joint bookrunners for the offering.

Cystic fibrosis drug developer Sionna Therapeutics hopes to join the IPO wave started by Metsera and Maze Therapeutics last ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...

Stay updated on the latest financial news and upcoming IPOs/SPACs with this article covering Titan America, Smithfield Foods, ...

Monday saw the release of JMP Securities' latest industry overview for the biotechnology sector, which highlighted key events from January 2025. The report noted a modest resurgence in the sector, ...